NTLA
$12.18
Revenue | $9.11Mn |
Net Profits | $-135.71Mn |
Net Profit Margins | -1489.54% |
Intellia Therapeutics Inc.’s revenue fell -24.02% since last year same period to $9.11Mn in the Q3 2024. On a quarterly growth basis, Intellia Therapeutics Inc. has generated 30.96% jump in its revenue since last 3-months.
Intellia Therapeutics Inc.’s net profit fell -11.04% since last year same period to $-135.71Mn in the Q3 2024. On a quarterly growth basis, Intellia Therapeutics Inc. has generated 7.66% jump in its net profits since last 3-months.
Intellia Therapeutics Inc.’s net profit margin fell -46.15% since last year same period to -1489.54% in the Q3 2024. On a quarterly growth basis, Intellia Therapeutics Inc. has generated 29.49% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -1.38 |
EPS Estimate Current Year | -1.38 |
Intellia Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.38 - a -12.2% fall from last quarter’s estimates.
Intellia Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -1.38.
Earning Per Share (EPS) | -1.34 |
Intellia Therapeutics Inc.’s earning per share (EPS) jumped 2.9% since last year same period to -1.34 in the Q3 2024. This indicates that the Intellia Therapeutics Inc. has generated 2.9% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-09 | -1.38 | -1.12 | 18.84% |
2024-08-08 | -1.23 | -1.52 | -23.58% |
2024-11-07 | -1.38 | -1.34 | 2.9% |